This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
3b4y
From Proteopedia
m (Protected "3b4y" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:3b4y.png|left|200px]] | ||
| - | |||
| - | <!-- | ||
| - | The line below this paragraph, containing "STRUCTURE_3b4y", creates the "Structure Box" on the page. | ||
| - | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
| - | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
| - | or leave the SCENE parameter empty for the default display. | ||
| - | --> | ||
{{STRUCTURE_3b4y| PDB=3b4y | SCENE= }} | {{STRUCTURE_3b4y| PDB=3b4y | SCENE= }} | ||
| - | |||
===FGD1 (Rv0407) from Mycobacterium tuberculosis=== | ===FGD1 (Rv0407) from Mycobacterium tuberculosis=== | ||
| + | {{ABSTRACT_PUBMED_18434308}} | ||
| - | + | ==Function== | |
| - | + | [[http://www.uniprot.org/uniprot/P96253_MYCTU P96253_MYCTU]] Catalyzes the coenzyme F420-dependent oxidation of glucose 6-phosphate to 6-phosphogluconolactone. Is essential for the bioreductive activation of the prodrug PA-824 (nitroimidazo-oxazine) developed for anti-tuberculosis therapy against both replicating and persistent bacteria. It does not interact directly with PA-824 but, rather, provides reduced F420 to an accessory protein (Rv3547), which in turn activates PA-824. Also probably has a role in resistance to oxidative stress, via its consumption of G6P that serves as a source of reducing power to combat oxidative stress in mycobacteria.<ref>PMID:10879539</ref><ref>PMID:18434308</ref> | |
| - | + | ||
| - | + | ||
| - | --> | + | |
| - | + | ||
==About this Structure== | ==About this Structure== | ||
| Line 22: | Line 10: | ||
==Reference== | ==Reference== | ||
| - | <ref group="xtra">PMID:018434308</ref><references group="xtra"/> | + | <ref group="xtra">PMID:018434308</ref><references group="xtra"/><references/> |
[[Category: Mycobacterium tuberculosis h37rv]] | [[Category: Mycobacterium tuberculosis h37rv]] | ||
[[Category: Baker, E N.]] | [[Category: Baker, E N.]] | ||
| Line 29: | Line 17: | ||
[[Category: Squire, C J.]] | [[Category: Squire, C J.]] | ||
[[Category: TBSGC, TB Structural Genomics Consortium.]] | [[Category: TBSGC, TB Structural Genomics Consortium.]] | ||
| + | [[Category: F420 binding]] | ||
| + | [[Category: Non-prolyl cis-peptide bulge]] | ||
| + | [[Category: Oxidoreductase]] | ||
| + | [[Category: Structural genomic]] | ||
| + | [[Category: Tb structural genomics consortium]] | ||
| + | [[Category: Tbsgc]] | ||
| + | [[Category: Tim-barrel]] | ||
Revision as of 09:19, 27 March 2013
Contents |
FGD1 (Rv0407) from Mycobacterium tuberculosis
Template:ABSTRACT PUBMED 18434308
Function
[P96253_MYCTU] Catalyzes the coenzyme F420-dependent oxidation of glucose 6-phosphate to 6-phosphogluconolactone. Is essential for the bioreductive activation of the prodrug PA-824 (nitroimidazo-oxazine) developed for anti-tuberculosis therapy against both replicating and persistent bacteria. It does not interact directly with PA-824 but, rather, provides reduced F420 to an accessory protein (Rv3547), which in turn activates PA-824. Also probably has a role in resistance to oxidative stress, via its consumption of G6P that serves as a source of reducing power to combat oxidative stress in mycobacteria.[1][2]
About this Structure
3b4y is a 2 chain structure with sequence from Mycobacterium tuberculosis h37rv. Full crystallographic information is available from OCA.
Reference
- Bashiri G, Squire CJ, Moreland NJ, Baker EN. Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol Chem. 2008 Jun 20;283(25):17531-41. Epub 2008 Apr 22. PMID:18434308 doi:10.1074/jbc.M801854200
- ↑ Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000 Jun 22;405(6789):962-6. PMID:10879539 doi:10.1038/35016103
- ↑ Bashiri G, Squire CJ, Moreland NJ, Baker EN. Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol Chem. 2008 Jun 20;283(25):17531-41. Epub 2008 Apr 22. PMID:18434308 doi:10.1074/jbc.M801854200
